Assessment of the QT Interval Using a Smartphone ECG Device during Antiarrhythmic Drug Initiation

Overview

  • Study type

    Observational
  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Rochester, Minnesota: 17-009775
    Sponsor Protocol Number: 17-009775

About this study

  1. Obtain AliveCor ECG Recordings from subjects at the time of clinically indicated ECGs over the course their anti-arrhythmic drug loading hospital admission. 
  2. Create and refine an AliveCor algorithm to accurately measure a patient’s QT interval and heart rate corrected QTc value and validate/compare the results against the 12- lead ECGs on record.
  3. Obtain AliveCor ECG recordings at the time of daily clinically indicated electrolyte panels to further develop and refine a Potassium screening algorithm.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria:

  • Patients 18 and older  
  • Admitted to the hospital for initiation of dofetilide or sotalol on the basis of routine electrophysiologic care (no patients will specifically receive dofetilide or sotalol because of their participation in this research study). 

Exclusion Criteria:

  • Patients  <18 years of age
  • Patients admitted for dose adjustments, or following non-standard dosing protocols, will be excluded
  • Patients without the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Peter Noseworthy, M.D.

Open for enrollment

Contact information:

Trena Thome

Thome.Trena@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20401451

Mayo Clinic Footer